Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer

被引：37

作者：

Tateishi, Ukihide ^{[1
]}

机构：

[1] Tokyo Med & Dent Univ, Dept Diagnost Radiol, Tokyo, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 50卷 / 04期

关键词：

PET; PET/CT; PSMA; prostate cancer; prostate-specific membrane antigen; BONE-SCAN INDEX; PSMA INHIBITOR; PRECLINICAL EVALUATION; PET/CT; LIGAND; PROBE;

D O I：

10.1093/jjco/hyaa004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

From a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for both diagnosis and radioligand therapy (RLT) of prostate cancer. The term 'specific' has been used to characterize a histologic hallmark of overexpression in the membrane of most prostate cancer. Many PSMA ligands have been developed since the previous decade and have been used in several clinical trials and clinical studies. However, procedure, specification, protocol, interpretation criteria, radiation dose, and cost-effectiveness of PSMA ligands have not been fully explained. Regardless of worldwide use of promising PSMA-ligand PET and RLT, it has not been approved in Japan. Expedited introduction of PSMA-ligand PET and RLT to Japan and implementation of clinical study are eager for many patients with prostate cancer.

引用

页码：349 / 356

页数：8

共 37 条

[1] Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience [J].

Afshar-Oromieh, A. ;

Haberkorn, U. ;

Schlemmer, H. P. ;

Fenchel, M. ;

Eder, M. ;

Eisenhut, M. ;

Hadaschik, B. A. ;

Kopp-Schneider, A. ;

Roethke, M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) :887-897

[2] A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition [J].

Anand, Aseem ;

Morris, Michael J. ;

Kaboteh, Reza ;

Reza, Mariana ;

Tragardh, Elin ;

Matsunaga, Naofumi ;

Edenbrandt, Lars ;

Bjartell, Anders ;

Larson, Steven M. ;

Minarik, David .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (12) :1865-1871

[3]

[Anonymous], 2019, EUR UROL

[4] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Wirtz, Martina ;

Wiessalla, Stefan ;

Schottelius, Margret ;

Mueller, Dirk ;

Klette, Ingo ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013

[5] Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer [J].

Behr, Spencer C. ;

Aggarwal, Rahul ;

VanBrocklin, Henry F. ;

Flavell, Robert R. ;

Gao, Kenneth ;

Small, Eric J. ;

Blecha, Joseph ;

Jivan, Salma ;

Hope, Thomas A. ;

Simko, Jeffry P. ;

Kurhanewicz, John ;

Noworolski, Susan M. ;

Korn, Natalie J. ;

De Los Santos, Romelyn ;

Cooperberg, Matthew R. ;

Carroll, Peter R. ;

Nguyen, Hao G. ;

Greene, Kirsten L. ;

Langton-Webster, Beatrice ;

Berkman, Clifford E. ;

Seo, Youngho .

JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) :910-916

[6] Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors [J].

Benesova, Martina ;

Bauder-Wuest, Ulrike ;

Schaefer, Martin ;

Klika, Karel D. ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) :1761-1775

[7] Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].

Benesova, Martina ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Afshar-Oromieh, Ali ;

Kratochwil, Clemens ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920

[8] Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] [J].

Calais, Jeremie ;

Czernin, Johannes ;

Fendler, Wolfgang P. ;

Elashoff, David ;

Nickols, Nicholas Nicholas G. .

BMC CANCER, 2019, 19 (1)

[9] [18F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance [J].

Chen, Ying ;

Lisok, Ala ;

Chatterjee, Samit ;

Wharram, Bryan ;

Pullambhatla, Mrudula ;

Wang, Yuchuan ;

Sgouros, George ;

Mease, Ronnie C. ;

Pomper, Martin G. .

BIOCONJUGATE CHEMISTRY, 2016, 27 (07) :1655-1662

[10] 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer [J].

Chen, Ying ;

Pullambhatla, Mrudula ;

Foss, Catherine A. ;

Byun, Youngjoo ;

Nimmagadda, Sridhar ;

Senthamizhchelvan, Srinivasan ;

Sgouros, George ;

Mease, Ronnie C. ;

Pomper, Martin G. .

CLINICAL CANCER RESEARCH, 2011, 17 (24) :7645-7653

← 1 2 3 4 →